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The World Health Organization recently launched its 2021-2030 
roadmap, Ending the Neglect to Attain the Sustainable Development 
Goals, an updated call to arms to end the suffering caused by 
neglected tropical diseases. Modelling and quantitative analyses 
played a significant role in forming these latest goals. In this 
collection, we discuss the insights, the resulting recommendations 
and identified challenges of public health modelling for 13 of the 
target diseases: Chagas disease, dengue, gambiense human African 
trypanosomiasis (gHAT), lymphatic filariasis (LF), onchocerciasis, 
rabies, scabies, schistosomiasis, soil-transmitted helminthiases (STH), 
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Taenia solium taeniasis/ cysticercosis, trachoma, visceral leishmaniasis 
(VL) and yaws. This piece reflects the three cross-cutting themes 
identified across the collection, regarding the contribution that 
modelling can make to timelines, programme design, drug 
development and clinical trials.
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A renewed roadmap for a new decade
The World Health Organization’s (WHO) 2021-2030 Neglected 
Tropical Disease (NTD) Roadmap was launched on January 28th, 
2021, renewing the commitment of the global NTD community 
to end the suffering caused by these diseases1. The development 
of the roadmap was guided by extensive global stakeholder con-
sultation, including consultation with mathematical and statis-
tical modellers. Modellers were asked to assess the technical 
feasibility of proposed goals, to identify major challenges for 
achieving the new goals from a transmission dynamics per-
spective, possible acceleration strategies, and key outstand-
ing research questions2. Technical commentaries have been 
published as a collection in Gates Open Research3–15, which 
detail these insights for 13 NTDs: Chagas disease, dengue, 
gambiense human African trypanosomiasis (gHAT), lymphatic 
filariasis (LF), onchocerciasis, rabies, scabies, schistosomiasis, 
soil transmitted helminthiases (STH), Taenia solium taeniasis/ 
cysticercosis, trachoma, visceral leishmaniasis (VL) and yaws.
Neglected tropical diseases continue to affect over one billion 
people16 as the result of the considerable inequalities in glo-
bal healthcare systems that fail to support those most in need17. 
The burden of NTDs falls largely on the poorest communi-
ties, resulting in an unrelenting cycle of poverty that is driven 
by negative social, health and economic impacts of infection on 
individuals and families, augmenting existing social divides. 
For infections with a substantial zoonotic component, morbidity 
and mortality among livestock also affect people’s livelihood 
with economic impacts that transcend medical implications. 
Notable progress to reduce the burden of NTDs has been 
made as a result of the commitments made in 2012 through the 
WHO 2020 NTD Roadmap18 and the London Declaration on 
NTDs19. As a result, 500 million people no longer require 
interventions against several NTDs and 40 countries, territo-
ries and areas have eliminated at least one disease1. These wins 
are the outcome of concerted and consolidated efforts from 
endemic communities and invaluable volunteers, governments, 
donor agencies and the pharmaceutical industry. Despite such 
early gains, reaching the endgame presents some of the greatest 
challenges – namely sustaining those early gains whilst iden-
tifying and averting small numbers of sparsely distributed 
cases. The 2030 roadmap is shaped around three pillars that 
aim to support global efforts to maintain the gains, address the 
challenges and ultimately combat NTDs1: 1. Accelerating pro-
grammatic action. 2. Intensifying cross-cutting approaches and 
3. Shifting operating models and culture to facilitate in country 
ownership.
The use of mathematical and statistical modelling in NTD 
research and policy has until recently, and with a few exceptions 
(e.g., onchocerciasis20), lagged behind other groups of infectious 
diseases that receive more focus and funding (often, dis-
eases that impact wealthier individuals and nations, or 
those perceived to potentially impact these). However, this is 
changing with the advent of groups like the NTD Modelling 
Consortium21, who have developed the Policy-Relevant Items 
for Reporting Models in Epidemiology of Neglected Tropical 
Diseases (PRIME-NTD) principles, as a guide to communicate 
the quality and relevance of modelling to stakeholders20. This 
has added clout to the call for modelling in the policy arena 
as well as setting a high bar of best practice for the wider 
modelling community. Having now gained significant traction, 
the use of modelling in NTD policy has contributed to new 
intervention tools22, vector control strategies23–26, shaped policy 
responding to COVID-19-related programme disruptions27–35 
and has aided in the development of WHO guidelines36,37. 
For this positive relationship to continue, it is imperative to 
invest in a mutual understanding through ongoing conversa-
tion between policy-makers and modellers, to determine what 
kind of questions are the “right” questions, how to interpret 
uncertainty and what the models can and cannot be used 
for.
This piece introduces a collection of papers borne of a meeting 
in Geneva, in April 2019 attended, among others, by the NTD 
Modelling Consortium and convened by the WHO: Achieving 
NTD control, Elimination and Eradication Targets Post-2020; 
Modelling Perspectives & Priorities2. As new management tar-
gets and strategies took shape, the meeting provided policy 
makers and modellers the space to ask and answer specific 
questions regarding the proposed 2030 goals and the intended 
strategies to achieve them. Although the roadmap covers a 
range of diseases with diverse epidemiologies and differing 
management recommendations, the priority questions identi-
fied by modelers and stakeholders during the 2019 meeting 
and echoed by the authors of the technical commentaries 
shared three similar themes that should be considered in NTD 
modelling moving forward: timelines, programme design, 
and clinical study design. 
Timelines
Goals are only worth setting in the context of time. It is therefore 
not surprising that many of the technical commentaries in this 
collection identified timelines as a priority issue. The public 
health and economic benefits of reaching goals are innumerable 
but can only be achieved by the target year through appropri-
ate mobilisation of diverse resources. Modelling in the forms 
of past inference and forward projections can align many 
moving parts (for example epidemiological, demographic, and 
social considerations) to inform our understanding of the 
reasons why programmes succeed or fail38,39. Forecasts have 
played a crucial role in understanding whether the 202040 and 
associated collection41,42, 202543 and 20303–15,34 goals can 
be reached under current strategies with the caveat that 
long-term predictions naturally become more uncertain.
In some instances, whether a goal can or will be met on 
time is relatively easy to ascertain – for example it is 
a resounding no for leprosy and rabies, which are hindered 
by passive case control, long quiescent incubation periods, and 
inadequate investment in interventions15,44. Alternatively, the 
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goals for schistosomiasis11, STH8, and onchocerciasis13 seem 
achievable in some or most settings, depending on localised 
parameters like baseline prevalence, and already experienced 
duration of and adherence to mass drug administration (MDA) 
programmes. In the case of T. solium, a lack of internation-
ally agreed goals for elimination or control curtails the ability 
to effectively model timelines; for example, the 2021-2030 NTD 
roadmap proposes the overall milestone of achieving “intensified 
control in hyperendemic areas”, without agreeing on technical 
definitions for T. solium endemicity levels, or defining 
measurable criteria for attaining “intensified” control14.
Programme design
The diseases considered by the London Declaration and WHO 
roadmaps are at differing stages in their trajectories. Whilst some 
are on the cusp of achieving their goals, others face political and 
epidemiological barriers to progress. Both scenarios raise sev-
eral priority questions regarding programme design, where ‘pro-
gramme’ can mean intervention or surveillance. In addition to 
determining success or failure within the defined intervention 
time frames, modelling has provided insights into key fac-
tors of operational design like the treatment coverage necessary 
to reach goals in a given setting. Where it may not be pos-
sible, models can be used to test the efficacy of separate 
and combined chemotherapeutic37 and non-pharmaceutical 
interventions23,45,46, including combined interventions that target 
multi-host systems for zoonotic NTDs14. Additionally, deciding 
the optimal timing47 or frequency48,49 of treatment, and know-
ing who to treat50,51 are essential to the success of all interven-
tions. Of course, the intervention strategies most likely to lead 
to achievement of the goals may not be sustainable in terms 
of cost to individuals, governments, or donors. By partnering 
highly  detailed transmission models with cost-effectiveness 
analysis, modelling can also contribute to tailored insights 
regarding the affordability and benefits versus costs of 
interventions52–62. Models can also be used to explore integra-
tion between NTD programmes, or to understand the potential 
cross-utility of existing NTD programmes on other helminth 
species, such as exploring the additional benefit of national schis-
tosomiasis control programmes using praziquantel on T. solium 
prevalence in co-endemic areas14. Understanding this cross-
utility is vital to intensifying cross-cutting approaches – one 
of the three core pillars of the roadmap, that differentiates the 
framework from its predecessor. 
These are all very practical features of intervention pro-
grammes that can in principle be planned for, but underly-
ing features of target populations and human nature can 
undermine these plans. Survey data in recent years have made 
it evident that whilst the aim may be to deliver treatment at 
a certain geographical and therapeutic coverage, it is not anal-
ogous with consumption, as treatment is systematically not 
ingested by some63,64, or is not disseminated to the full intended 
group, reducing the true coverage. There are a variety of 
reasons for this65,66, but it is likely that similar mechanisms 
impact participation in surveillance, therefore biasing the 
estimates of prevalence, particularly when treatment and surveil-
lance are co-occurring (e.g., gHAT9,67, rabies15,68). Modelling 
shows that the impact of this variable true coverage depends 
on the pathogen in question and transmission intensity64,69–71 
but it undoubtedly has an impact on reaching public health 
goals72,73.
Once a strategy has been deemed effective and prevalence 
targets are attained, it is likely that these interventions either 
transition, such as going from MDA to identified case manage-
ment, or they stop all together. Establishing robust surveillance 
strategies at this point is vital, but obviously not everyone 
can be regularly sampled and not every incident infection 
case will be detected. Stochastic events like reinfection and 
reintroduction are risks that can drive resurgence. Modelling 
can support the identification of the optimal surveillance 
strategy and determine which prevalence or intensity indica-
tors need to be monitored to ensure the desired public health 
goal74–76, although challenges remain in developing long-term 
strategies77. Modelling can make useful contributions in 
developing sustainable, effective interventions and surveillance 
strategies and should therefore be included in any programmatic 
design from the start. As embodied by the 2021-2030 NTD 
roadmap, impactful interventions cannot be achieved by 
working in silos, but instead require continuous communication 
between all parties of an interdisciplinary team.
Drug development and clinical study design
Though modelling is increasingly used in public health deci-
sion making, the use of modelling to direct clinical trial design 
and drug development is not so common, and even less so 
for NTDs. To reach goals like elimination as a public health 
programme (trachoma, STH, schistosomiasis and LF) and elimi-
nation of transmission (onchocerciasis) novel drug development 
will be critical1,4,5,11,13,78. However, financial returns on invest-
ments into NTDs are limited and therefore largely unappealing, 
particularly because of the heavy reliance by endemic nations, 
on donations from pharmaceutical producers. Increased use 
of mathematical modelling could reduce the financial waste 
associated with the drug-development-to-distribution-pipeline78. 
If we consider this pipeline in three parts; pre-clinical, clini-
cal trial and distribution, it is clear that modelling can pro-
vide valuable insight at each stage. Onchocerciasis and LF have 
recently benefited from pharmacokinetic-pharmacodynamics 
modelling, translating pre-clinical non-human experimental 
results into quantitative insights relevant to human treatment79. 
Clinical trial simulations are designed to include all aspects of a 
clinical trial protocol including (but not limited to) recruitment 
criteria, drug properties/ effectiveness and follow-up times80, 
providing valuable guidance that translates into more effec-
tive, efficient, cost-efficient and robust clinical trials. In addi-
tion to providing insight into the optimal distribution of new 
drugs81, rethinking the distribution of existing drugs to achieve 
public health targets can also be guided by modelling37,48.
Challenges
Modelling has certainly addressed many of the key ques-
tions asked of modellers at the 2019 meeting2. However, 
cross-disease challenges remain82. The most common of 
these, highlighted by all groups involved in the meeting 
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report2 and this collection, is undoubtedly a lack of data or poor 
data quality. This could be because certain parameters simply 
cannot be measured; because of vast heterogeneity or because 
they have yet to be collected83. For example, VL has a highly 
variable incubation period, unknown duration of asymptomatic 
infection and estimates for the duration of lasting immunity 
are ill-defined6,84,85, introducing uncertainty into the tempo-
ral dynamics underlying any projections. Chagas disease, 
gHAT and leprosy also suffer from indeterminate incubation 
periods9,12,21 impacting case detection and adding greater uncer-
tainty in epidemiological estimates fitted to by models85,86. 
Asymptomatic or pre-symptomatic infection is common 
of many NTDs and presents a significant challenge to their 
management. For example, asymptomatic VL infections can-
not be treated, whereas it is possible to teat asymptomatic 
gHAT but only if it is able to be detected. Identifying their 
respective proportions in an infected population, particularly in 
the absence of high surveillance coverage, means account-
ing for this group using roundabout methods and proxy 
diagnostics6,9.
Many diagnostics are indirect, proxy measures of case detec-
tion, often with less than perfect sensitivity or specificity87,88, 
and have a direct effect on perceived prevalence and individual 
burdens of infection89,90. Given that models are only as good 
as the data to which they are fitted, this has a significant impact 
on the utility of model results. For example, in the instances 
of STH and intestinal schistosomiasis (Schistosoma mansoni), 
WHO targets are given in terms of eggs per gram of faecal 
matter as detected with the Kato-Katz method, which noto-
riously suffers from poor sensitivity, particularly for low 
intensity infections91, invariably underestimating prevalence. 
Where a multi-host system is present for zoonotic NTDs, 
though it is possible to measure infection through direct 
observation of parasite stages in the animal host(s)14, 
via necropsy or other methods92, it is likely that this approach 
is inappropriate for monitoring and evaluating the likes of 
T. solium control programmes, due to the large animal 
sample sizes required to detect a statistically meaningful 
impact on transmission, especially in low prevalence settings14. 
Molecular xenomonitoring (testing vectors for the parasite 
instead of human hosts) for LF and onchocerciasis has shown 
promise93 but operational research gaps remain, impacting 
large-scale utilisation94. Reconciling these different streams 
of imperfect diagnostic data will be key to their utility in 
modelling and indeed to reaching and sustaining public 
health goals.
The operational units over which epidemiological data are 
collected, and projections made are also often over somewhat 
arbitrary administrative borders that infectious diseases do 
not adhere to. For rabies, non-spatial models are inadequate 
for capturing the low-endemicity incidence rates15 such that 
more data-intensive modelling approaches are required. In 
addition to questionable detection success, VL surveillance 
has operated over geographical units that are too large to 
evaluate the success of control methods6, despite modelling 
showing that transmission is highly localised over smaller 
spatial scales (i.e. 85% of inferred transmission distances 
≤300m)95. Similarly for onchocerciasis, modelling shows that the 
rate at which interventions can be scaled down depend strongly 
on the spatial units of assessment13,96. Clustering of T. solium 
porcine cysticercosis around human taeniasis carriers, particu-
larly evident in South American communities, demonstrates the 
need for spatially explicit models in certain settings14,97, such 
as the recently developed CystiAgent model for Peru98, capa-
ble of testing spatially structured interventions. From this it is 
evident that whilst spatial heterogeneity requires nuanced 
model structure, the leading challenge here is the paucity 
of data at the spatial level necessary to parameterise the 
models for spatially relevant insights. This will become ever 
more important as all NTDs move towards low-prevalence 
and spatially-heterogenous incidence patterns.
The assumptions made to overcome these uncertainties often 
differ across models – which then produce differing results. 
Whilst this is somewhat overcome by the practice of model 
comparison99,100, which highlights important biological and 
population processes that impact epidemiological trajectories, 
these unknowns wave a clear flag for collaborative opportunities 
between modellers, field epidemiologists and clinicians. 
Indeed, the optimal working relationship is a synergistic 
pathway, where the model’s needs drive data collection, the 
data shapes further model iterations, and these then inform 
policy and the outcomes at the programmatic and clinical 
level51,82,83,85,101–109. Improving communication between these 
groups is critical to achieving the desired public health 
gains20.
Conclusion
The increased use of mathematical and statistical modelling 
over the last decade has helped move the field of NTDs 
into a more quantitative space, providing the link between 
epidemiological concepts and observed reality. For modelling 
to continue to fill this role and influence decision-making, 
ongoing conversations and engagement between all parties will 
be paramount. These will, in turn, overcome the continuous 
challenges of data quality and access, and the consequent 
model assumptions required. As programme and disease 
management move towards a country-ownership framework 
under the new roadmap, it will be key that modelling follows 
suit, overcoming systematic notions of knowledge ownership 
and challenging associated power dynamics110–112. In this way, 
future modelling will work to support this new NTD 
landscape. 
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